COVID-19 and the Human Eye: Conjunctivitis, a Lone COVID-19 Finding – A Case-Control Study

Mocanu, Valeria; Bhagwani, Dharmesh; Sharma, Abhinav; Borza, Claudia; Rosca, Ciprian Ilie; Morariu, S.; Bhagwani, Shalini; Haidar, Laura; Lajwanti, Kshtriya; Kundnani, Nilima Rajpal; Horhat, Florin-Raul; Horhat, Raluca

doi:10.1159/000521808

Cited by 11 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Realizou-se revisão bibliográfica integrativa por meio de busca eletrônica nas bases de As características ou apresentação clínica da conjuntivite por COVID-19 podem se apresentar de forma diferente em pacientes com diagnóstico positivo da doença. A prevalência de conjuntivite em casos positivos de SARS-CoV-2 variou de 0,8% a 31,6%, sendo o valor mais alto (Mocanu et al, 2022;Wu et al, 2020). No entanto, quanto ao tipo de condição ocular, Inomata et al (Inomata et al, 2020) concluíram que a conjuntivite unilateral ou bilateral pode atingir valores elevados que variam até 86,4%.…”

Section: Métodounclassified

“…Em nossos resultados, as características ou sintomas mais comuns foram; epífora que oscilou entre 15% e 86% (Lalitha et al, 2022;Prajna et al, 2022;Ranzenigo et al, 2021), seguida de corpo estranho que atingiu entre 11,8% e 57,1% (Almazroa et al, 2022;Jin et al, 2021;Panoutsopoulos, 2020), secreção de 26,8% a 38,5% (Aggarwal et al, 2020;Jin et al, 2021;Prajna et al, 2022), coceira de 46% para 71% (Lalitha et al, 2022;Prajna et al, 2022), dor ocular que foi de 11,2% para 31,2% % (Aggarwal et al, 2020;Lalitha et al, 2022;Ranzenigo et al, 2021), hiperemia de 11,2% para 26,8% (Aggarwal et al, 2020;Binotti & Hamrah, 2022;Layikh et al, 2021;Mocanu et al, 2022;Ranzenigo et al, 2021), olho seco de 9,8% a 33,3% (Almazroa et al, 2022;Inomata et al, 2020), olho pegajoso com 10% (Ranzenigo et al, 2021), congestão conjuntival entre 5,0% a 28,8% % (Binotti & Hamrah, 2022;Chen et al, 2020;Jin et al, 2021;Layikh et al, 2021), visão turva que chegou a 12,7%…”

Section: Métodounclassified

“…Brazilian Journal of Health Review, Curitiba, v. 6, n. 1, p.433-443, jan./feb., 2023 Foi relatada uma prevalência variando de 0,8% a 31,6% de casos positivos para COVID-19 (Wu et al, 2020). A conjuntivite pode ter um quadro variável, demonstrando que a apresentação ocular unilateral pode acometer até 77,7% e bilateral 22% (Mocanu et al, 2022).…”

unclassified

See 2 more Smart Citations

Conjuntivite como manifestação oftalmológica de SARS-CoV-2 em indivíduos com Covid-19

Aucay¹,

González²,

Anaya³

et al. 2023

Braz. J. Hea. Rev.

View full text Add to dashboard Cite

Objetivo: descrever as características da conjuntivite como manifestação oftalmológica do SARS-CoV-2 em indivíduos com COVID-19. Método: foi realizada uma revisão integrativa de artigos publicados entre 2020 e 2022, utilizando a estratégia PICO para integrar a questão de pesquisa. As buscas eletrônicas foram realizadas nas bases de dados Pubmed (https://pubmed.ncbi.nlm.nih.gov/) e ScienceDirect (https://www.sciencedirect.com/), em espanhol ou inglês, usando descritores e operadores booleanos AND e OR. Foi realizada uma busca eletrônica para descrever as características da conjuntivite como manifestação oftalmológica do SARS-CoV-2 em indivíduos com COVID-19. Resultados: Foi identificado um registro total de 96 artigos, incluindo 14 estudos de pacientes que manifestaram conjuntivite por SARS-CoV-2 como manifestação de COVID-19. A conjuntivite como manifestação oftalmológica do SARS-CoV-2 em indivíduos com COVID-19 apresenta prevalência de 0,8% a 31,6%. As características mais comuns são; hiperemia conjuntival, epífora, sensação de corpo estranho e fotofobia. Conclusão: A conjuntivite pode ser uma parte inicial do quadro clínico da COVID-19, ou pode até se manifestar como o único sintoma que aparece dias antes, a incidência e as características da conjuntivite como manifestação oftalmológica da COVID-19 são variáveis.

show abstract

Section: Métodounclassified

See 1 more Smart Citation

Conjuntivite como manifestação oftalmológica de SARS-CoV-2 em indivíduos com Covid-19

Aucay¹,

González²,

Anaya³

et al. 2023

Braz. J. Hea. Rev.

View full text Add to dashboard Cite

show abstract

“…However, SARS-CoV-2 is a virus that rapidly evolved, leading to changes in the symptoms experienced by infected individuals. Therefore, Schulze et Bayer discussed the differences in signs from the first wave (Alpha) to the last waves (Omicron) regarding the symptomatic infection and symptoms from respiratory, GI, neurology, etc., and the symptoms changed evenly over time [54,55].…”

Section: Virus Variants Associated With Gastroenterology Syndromesmentioning

confidence: 99%

SARS-CoV-2 Variant-Specific Gastrointestinal Symptoms of COVID-19: 2023 Update

Slabakova,

Gerasoudis,

Miteva

et al. 2023

Gastroenterology Insights

View full text Add to dashboard Cite

The gastrointestinal (GI) tract may be a significant entrance or interaction site for SARS-CoV-2; therefore, the gut mucosal immune system participates in virus interaction as a first-line physical and immunological defense, leading to GI involvement and symptoms. This review focuses on the GI symptoms associated with SARS-CoV-2 infection while providing specific results on variant-specific signs and syndromes related to coronavirus disease 2019 (COVID-19). The pattern of symptoms changed during the virus evolution, since the data provided a current and thorough picture of the symptoms experienced by SARS-CoV-2 infected people, and variations in symptom patterns occurred as the Alpha, Delta, and Omicron variants have spread. Since the beginning of the pandemic, GI symptoms have been linked to SARS-CoV-2 infections, even though most infected people do not report them. For example, diarrhea (28.2%) was the most frequently reported GI symptom in the early phase of the pandemic. The most observed GI tract symptoms during COVID-19 were anorexia (loss of appetite), nausea, vomiting, diarrhea, and abdominal pain, usually in at least one-third of the patients. Mesenteric ischemia and GI bleeding were less observed but more severe. While GI symptoms are not associated with increased mortality, they complicate the disease, increase the duration of the illness, and result in worse outcomes. Nevertheless, it is accepted that symptoms between variants differ significantly, i.e., the Omicron variant causes milder COVID-19 than the Delta. Still, the rate of GI symptoms has declined in the following variant-dominated phases of the pandemic (Alpha: 19.4%, Delta: 17.9%, Omicron: 13.8%), which was also demonstrated for other GI signs associated with COVID-19.

show abstract

“…Testing to detect COVID-19 was implemented on a large scale. Symptoms varied from patient to patient, ranging from mild respiratory disease to the extent of multiorgan failure resulting in death [ 16 , 17 ]. The quality of life (QOL) of people was highly affected, especially in patients suffering from chronic illnesses such as atrial fibrillation, heart failure, multiple sclerosis, oncologic patients, etc., not just due to the difficulty of performing routine investigations, but also due to lockdown-induced anxiety and depression [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Non-Pharmacological Measures Implemented in the Management of the COVID-19 Pandemic in Romania

et al. 2022

Self Cite

View full text Add to dashboard Cite

The management of the COVID-19 pandemic in Romania has included the involvement of not only the medical system, but also that of the administrative and social services. All these organizations are working together to lower the impact on the health of the general population, to increase the health system’s response capabilities and even to diminish the negative effects upon the economy due to the epidemic’s length. Therefore, non-pharmacological measures (NPMs) imposed through restrictive measures (administrative, economic and individual) have influenced the evolution of morbidity and mortality. Even from the first months of the pandemic’s progression, researchers have shown the impact of the NPMs’ existence, as there were many studies on all NPMs in conjunction, as well as those targeting specific measures such as school closures. Our study started by establishing a temporal relationship between the non-pharmacological measures found in most countries (wearing a mask, washing hands and physical distancing, limiting economic activities, closing schools, limiting internal and international movement, banning public and private events in closed spaces) and the evolution of the pandemic in Romania. The degree of novelty brought by this study consists of extending the analysis to the pre-existing state of the health system and to the measures meant to increase the resilience of the population, as well as to the measures aimed at reducing the type of risk, and factors that can equally influence the evolution of the number of cases. The results of the statistical analysis show the important effects of certain NPMs (mask mandates, online schooling, decisions regarding imposing or lifting local restrictions) as well as the reduced impact of other measures (hand disinfection, social distancing or the restriction of public and private events). Hence, it can be concluded that during such pandemics, implementing quick, simple measures can prevent the spread of the disease and help fight the contagion in a better manner.

show abstract

COVID-19 and the Human Eye: Conjunctivitis, a Lone COVID-19 Finding – A Case-Control Study

Cited by 11 publications

References 29 publications

Conjuntivite como manifestação oftalmológica de SARS-CoV-2 em indivíduos com Covid-19

Conjuntivite como manifestação oftalmológica de SARS-CoV-2 em indivíduos com Covid-19

SARS-CoV-2 Variant-Specific Gastrointestinal Symptoms of COVID-19: 2023 Update

Evaluation of Non-Pharmacological Measures Implemented in the Management of the COVID-19 Pandemic in Romania

Contact Info

Product

Resources

About